

ScienceAbroad
The Organization of Israeli Scientists Abroad



A Window to the
**Israeli Pharma and
Biotech Industry**
Workshop's Agenda

April 3rd-7th, 2022



מדעניות ומדענים יקרים,

ברוכות וברוכים הבאים ל"סדנת החשיפה לתעשייה" הרביעית של ארגון ScienceAbroad. בשנים האחרונות, תעשיית ה-Life Science בישראל עוברת שינוי דרמטי. סטארטפים שונים ומיוחדים, השקעות עתק של גופים פרטים, ציבוריים ורשמיים של המדינה והרבה הרבה ידע וכשרון. במקביל, אחד מהאתגרים המשמעותיים של התעשייה הזו היא המחסור בכוח אדם מנוסה ואיכותי שייקח את התעשייה הזו קדימה ויסייע לה להתפתח ולהפוך את מדינת ישראל, מדינת ה-Startup Nation למדינת ה-Life Science Nation. שינוי שכזה יחולל דרמה אמיתית במשק הישראלי. הוא יסייע ביצירת אלפי מקומות עבודה לישראליות וישראלים, יגדל את הכנסות המדינה ממסים, יעודד השקעות נוספות בתחומים רבים ובעיקר, יעשה טוב לעולם כולו וידאג שכולנו נהיה בריאים יותר.

ההשתלבות שלכן ושלכם בתעשייה זו, מנהיגות ומנהיגי המחר של התעשייה, תעזור לה לצעוד קדימה ולחזק את מעמדה כתעשייה מצטיינת, מובילה ופורצת דרך – בדיוק כפי שמדינת ישראל יודעת לעשות. במהלך הימים הקרובים תפגשו, רק במעט, נציגי חברות מובילות במשק, תשמעו על המגמות העתידיות של התעשייה, על האתגרים, ההזדמנויות ועל הדרכים הנכונות להשתלב בה.

בהחלטה אסטרטגית שהתקבלה בארגון אנו מסייעים לכמה שיותר מדעניות ומדענים למצוא את מקומם בתעשייה בישראל, מתוך הבנה אמיתית שהעתיד לרבות ורבים מכן ומכם נמצא בעולם הזה. זאת מתוך הבנה שהשינוי הגדול לעולם מתחיל בעולם האקדמי וממשיך ביתר שאת בתעשייה, ושהמוצר הבא שישנה את העולם יגיע מכן ומכם ויביא גאוה וכבוד ענק למדינת ישראל.

ברצוננו להודות לכל השותפים שלנו לסדנה: לחברת TEVA השותפה האסטרטגית שלנו לסדנה זו ולפרויקטים נוספים; לאגפים לקליטה במדע וליזמות עסקית שבמשרד העלייה והקליטה על מימון מלגות הטיסה; לכל החברות, המרצות והמרצים שנרתמו ברצון להשתתף, ולאנשים הטובים שעמלו קשה להצלחתה.

אנחנו מאחלים לכל אחת ואחד מכם הצלחה מרובה בימים הקרובים ומקווים שבפעם הבאה תקנו חופשי חודשי ברכבת ישראל בדרך אל מקום העבודה החדש בישראל.

תמיד כאן לכל דבר ועניין,

ד"ר שמוליק הס
יו"ר הוועד המנהל

נדב דואני
מנכ"ל

עו"ד גלי טימור
מנהלת פיתוח עסקי ושותפויות

מדעניות ומדענים ישראלים יקרים,
ברוכים הבאים הביתה לישראל.

חברת טבע שמחה לתת חסות זו השנה הרביעית לסדנת "חשיפה לתעשיית הפארמה והביוטק" בישראל ולהיות שותפה לתמיכה במדענים ישראלים ובמחקר אקדמאי מוביל בארץ ובחו"ל.

סדנה זו מרגשת במיוחד לאחר שנתיים לא פשוטות שעברו על כולנו, שבהן הן הנסיעה הביתה והן ההתכנסויות מרחבי העולם היו הרבה יותר מאתגרות. אנו בטבע שמחים על חזרת המסורת המבורכת של אירוח המדענים השנה.

טבע, שהינה חברה גלובלית הפועלת ב-60 שווקים המתפרסים על פני הגלובוס, רואה כעת יותר מתמיד חשיבות אסטרטגית בבניית שיתופי פעולה מדעיים עם מוסדות אקדמאים וחוקרים מובילים בארץ ובעולם. מערכת יחסים הדוקה עם האקדמיה כבר מהשלבים המוקדמים יכולה להוביל לפיתוח תרופות מתקדמות וטכנולוגיות חדשניות לטובת מיליוני מטופלים ברחבי העולם.

אנו מאמינות כי היכולות והניסיון שאתם מביאים עמכם וההתנסויות במעבדות המחקר המובילות בעולם בעת שהותכם בחו"ל, יוכלו לחזק ולתרום רבות - הן לתעשיית הביוטק והפארמה והן לאקדמיה הישראלית - להמשיך להתפתח ולעמוד בחזית המדע בעולם.

חברת טבע גאה במרכזי המו"פ שלה בישראל (המרכז האינובטיבי בנתניה והמרכז הגנרי בכפר-סבא) - שהינם מהגדולים והמתקדמים בארץ וכן בחטיבת המו"פ הגלובלית של טבע בהם תבקרו במהלך השבוע.

במהלך השבוע הקרוב תוכלו להתרשם ולהיפגש עם מדעני וחוקרי חברת טבע המתמחים בפיתוח תרופות חדשניות וגנריות - כימיות וביולוגיות כאחד. עת חזרתכם לישראל נשמח לראותכם משתלבים בטבע ובתעשיית הביוטק הפורחת בישראל.

אנו מודות לארגון "סיינסאברוד" על היוזמה והשותפות ארוכת השנים בקיום הסדנה ומאחלות לכם סדנה פורייה, חווייתית ומרתקת.

Best regards,

מיכל חומסקי,
מנהלת יחסי ממשל ישראל, טבע

דר. דנה בר-און,
מנהלת קשרי אקדמיה, R&D, טבע

A Window to the Industry Workshop's Agenda

April 3-7, 2022

Introduction to Drug Development, Medical Device, and Personalized Medicine

Location: Google Campus (Ha'Omanim st. 12, Tel Aviv)

Day 1: Sunday, April 3rd 2022

Time	Agenda Items	Speaker
9:00- 9:30	Registration and refreshments	
9:30-10:00	Greetings	
10:00-11:30	Introduction of the participants (I-TED)	
11:30-12:30	Coffee & Networking break	
12:30-13:00	Introduction to drug development	Dr. Gili Hart , CEO, SpilSense
13:00-13:30	Introduction to personalized medicine	Dr. Daphna Laifenfeld , Co-founder and Chief Strategy Officer, Genetika+
13:30-14:00	Start-ups technologies – Success/failure parameters	Mr. Zohar Gendler , Managing Partner and CEO, NGT3
14:00-15:00	Lunch break	
15:00-19:00	Workshop - Digital Blue Ocean	Prof. Yesha Sivan , CEO & founder, DigitalRosh
	Most businesses - small and large - operate in more or less the same parallel niches. The result is very big competition in every field, a kind of "first come, first served". This condition is called in the language of the blue ocean "red ocean" - that is, an ocean saturated with the blood of competitors. But what if we could, instead of trying to beat our competitors, simply make them irrelevant? In the workshop we will reveal the difficulty points that limit the industry we are in and choose the right course for creating the blue ocean.	
19:00-20:00	Pizza & Beer evening	



The Big Pharma World | Location: Teva, Ha-Trufa st. 12, Netanya

Day 2: Monday, April 4th 2022

Time	Agenda Items	Speaker
9:30-11:00	Festive Passover Toast of the Teva Innovative R&D Site in Natanya with R&D and Teva management, Special Concert Show	
11:00-11:15	Welcome and Introduction to Teva	Yael Marantz , PhD, Head of Nonclinical Development and Head of Specialty R&D Site Abic
11:15-11:45	From an Idea to a Drug: Introduction to Drug Discovery and Development	Aric Orbach , DVM, Head of Pharmacology
11:45-12:15	On the Safe Side – introduction to toxicology and safety aspects of drug development	Hilla Kedar , PhD, Head of Nonclinical Safety
12:15-12:30	Coffee Break	
12:30-13:00	New Aspects and Trends in Clinical Trials Design	Eran Harary , MD, Head of Global Specialty R&D
13:00-14:00	Lunch Break	
14:00-15:00	Tour of the specialty R&D labs	Inbal Ben Eliezer , PhD, Head of in vivo pharmacology , Ilanai Fishbein , PhD, Head of In Vitro Pharmacology
15:00-15:30	A Window into the Intellectual Property of the Biotech Industry	Sharon Hausdorff , PhD, Chief Patent Counsel
15:30-18:30	BioPharma Hackathon – How to Turn Academic Innovation into an Invention? Ideation & Team Build	Dana Bar-On , PhD, Head of Academic Affairs and Networks, Sara Shnider , PhD, Academic Affairs and Networks



The Biotech Startup Ecosystem

Location: McKinsey & Company, HaArba'a st. 30, Tel Aviv, 23 floor

Day 3: Tuesday, April 5th 2022

Time	Agenda Items	Speaker
9:30-10:00	Gathering	
10:00-10:20	The future of Israeli Biomedical Innovation	Dr. Yaron Daniely , Partner & Head of aMoon Alpha
10:20-10:40	Mitochondrial augmentation technology: from bench to bedside	Dr. Noa Sher , Chief Scientist, Minovia Therapeutics
10:40-11:00	Things you can only do in a company and things you can only do in Academy	Prof. Yanay Ofra n, CEO, Biologic Design
11:00-11:30	Coffee & Networking break	
11:30-11:50	21 st century Biologists - Bridging the Data Insight Gap	Prof. Shai Shen-Orr , Chief Science Officer, CytoReason
11:50-12:10	Novocure – From an Israeli start-up to a global oncology company	Dr. Uri Weinberg , Chief Science Officer, Novocure
12:10-12:30	Managing creative research	Prof. Oded Shoseyov , PhD, Plant Molecular Biology and Nano Biotechnology, The Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem
12:30-13:00	Coffee & Networking break	
13:00-13:40	HR Panel	Moderator: Dr. Shmulik Hess , CEO, Valin Technologies Members: Hadas Banai , Head of Danel Biotech Iris Almosni , Talent Acquisition Israel Lead, Teva Limor Lior , MSc, HR Director, Minovia Therapeutics Mia Bloch , Recruiting Manager, McKinsey & Company Rony Lann , CEO, L-il Executive Search Tali Bonjack , HR Director, CytoReason
13:40-14:00	Networking break	



The Biotech Startup Ecosystem

Location: McKinsey & Company, HaArba'a st. 30, Tel Aviv, 23 floor

Day 3: Tuesday, April 5th 2022

Time	Agenda Items	Speaker
14:00-15:00	Lunch break	
15:00-15:20	Leveraging industrial biotechnology to tackle climate change and ensure food security	Dr. Tami Dvash , VP R&D for Meat Products, Aleph Farms
15:20-15:40	First Rare then Dare- Fulfilling the Promise of Lentiviral Gene Therapy	Dr. Noam C. Diamant , Co-founder & CEO, NOGA Therapeutics
15:40-16:10	Coffee & Networking break	
16:10-16:30	Clexio Biosciences	Elisabeth Kogan , CEO and Co-founder, Clexio Biosciences
16:30-17:20	Returning scientists panel	Moderator: Dr. Ianai Fishbein , Director, Head of in vitro pharmacology, Teva Members: Dr. Liron Rabany , Chief Scientist, Theranica Dr. Moshe Ben David , CTO, Ukko Dr. Noa Molshatzki , Senior Statistician, Cytoreason Dr. Omer Stern , Senior Manager, Academic Affairs and Networks, Teva
9:00-18:00	Job Interviews	
19:00-21:00	The Future of Digital Health and Biotech	Joint invite-only event – Grove Ventures & the Embassy of Switzerland (Ramat-Gan)



Field Tours

Location: Kfar Saba / Rehovot / Nes Ziona

Day 4: Wednesday, April 6th 2022

Time	Agenda Items	Speaker
9:00-9:30	Gathering at Teva – Eli Hurvitz Rd 18, Kefar Sava	
9:30-11:30	Teva, Kfar Saba - Drug Development- how does it look like?	Dr. Daniella Gutman , VP, Generic R&D and site head Israel & Hungary, Teva
11:30-12:30	Travel to Rehovot	
12:30-13:30	Lunch at AION Labs	
13:30-14:00	AION Labs: the best opportunity and environment for you to found your Start-up	Mati Gill , CEO, AION Labs
14:00-14:30	Israel Biotech Ecosystem	Dr. Yuval Cabilly , Co-Founder and Managing Partner, IBF – Israel Biotech Fund
14:30-15:00	Walk to Enlivex, Nes Ziona	
15:00-16:30	Enlivex - A glimpse to the cell therapy space	Dr. Oren HersHKovitz , CEO, Enlivex Therapeutics



From Academic Innovation to Inventions - Mini Hackathon

Location: Salesforce, Yigal Alon st. 94, Alon 1 Tower, 11 Floor, Tel Aviv


Day 5: Thursday, April 7th 2022

Time	Agenda Items	Speaker
9:00-9:15	Gathering	
9:15-18:00	Hacking - Ready, Set, Go!	
9:15-9:30	Introduction and Hackathon Framework	Dr. Dana Bar-On , Senior Director, Head of Academic Affairs and Networks, Teva
09:30-17:00	Working in teams with mentors Team workshops How to pitch, presentation tips, patent search, product, business models, etc.	
14:00-14:30	Arkin Bio investments - The Devil is in the Details	Dr. Pini Orbach , Head of Pharma, Arkin Holdings Dr. Alon Lazarus , Biotech Investment Manager, Arkin Holdings
16:30	Dry runs with peer review	
19:00-21:00	Meetup with Israeli senior industry executives	
20:15-20:45	Hackathon presentations and Voting by Jury Members (5 min for each team)	
20:55	Announcing the winners	

▶ A Window to Industry Workshop

Speakers - 2022

▶ Dr. Alon Lazarus - Biotech Investment Manager, Arkin Holdings



Dr. Alon Lazarus joined Arkin Holdings' pharma division in 2013. He serves on the board of several of Arkin's pharmaceutical companies, including Keros Therapeutics, and Lutris Pharma.

Prior to joining Arkin, Dr. Lazarus worked for the healthcare business development department of Yissum, the R&D arm of the Hebrew University of Jerusalem.

Dr. Lazarus holds a Ph.D. in molecular biology and an MBA, both from the Hebrew University of Jerusalem.

▶ Dr. Aric Orbach - DVM, Senior Director, Head of Pharmacology, Teva



Aric obtained his bachelor's degree in Biology at the Givat Ram campus of the Hebrew University. He then went on to study veterinary medicine at the Koret School of Veterinary Medicine (Hebrew University). Recently he received an M.B.A from the Peres Academic Center in Rehovot. As a veterinarian, Aric worked on several veterinary projects and served as a practitioner in a small animal clinic in Rishon Lezion. Aric joined Teva's R&D in 2001, starting in the non-clinical safety unit, followed by working as a "project leader", overseeing project development from early preclinical studies advancing to clinical stages. Currently, Aric heads the pharmacology department and works with a team of scientists to provide in-depth insights on drug candidate's activity and potential therapeutic benefits

▶ Dr. Dana Bar-On-Senior Director, Head of Academic Affairs and Networks, Teva



Dr. Bar-On is heading a global team, managing all of Teva's scientific R&D collaborations and strategic partnerships with academia. Previously to her role in Teva, she was the head of the industry-academia cooperation at the Sagol School of Neuroscience in Tel Aviv University, the largest neuroscience school in Israel. Dr. Bar-On was the founder and head of BrainBoost and Minducate, two innovation and entrepreneurship centers aimed at creating and advancing new commercial academic ventures and start-ups in the field of brain disorders and neuroscience in general. Dr. Bar-On conducted her postdoctoral fellowship at Tel Aviv University in collaboration with Cambridge University focusing on developing approaches for early diagnosis of Parkinson's disease. She completed her Ph.D in Neurobiology focusing on super-resolution microscopy, simulations and modeling of synaptic proteins and her B.Sc and M.Sc in distinction in Biotechnology at Tel Aviv University. Dr. Bar-On served over the years as a scientific consultant at several leading financial, high-tech and incubators private firms and as a director at the EU Human Brain Project education and curriculum committee.

▶ Dr. Daniella Gutman - VP, Generic R&D and site head Israel & Hungary, Teva



Education: BSc and MSc in Chemistry Technion Israel, PhD in Chemistry, Weizmann Institute Israel, Post Doctorate in Chemistry, ZFL CIBA-GEIGY Basel, Switzerland. 28 years of R&D experience in pharmaceutical industries.

Joined TEVA in 2007, leading the Israel generic R&D responsible over development of generic drug products in various delivery forms. In addition, was responsible for the R&D of the international markets, gained experience in the different regulations and different market's needs. Experience in development of API and DP, regulations, management and transformation of organization aligned with organization strategy. Prior to joining Teva work in TARO pharmaceutical from 1992, served in several roles with increasing responsibility in the R&D.

► Speakers - 2022

► Dr. Daphna Laifenfeld – Co-founder and Chief Strategy Officer, Genetika+

Daphna was previously Chief Scientific Officer at Ibex Medical Analytics, a digital health company using AI and Big Data to create a new modality in cancer diagnostics and personalized medicine. In this role, Daphna led all scientific and regulatory activities of the company. Prior to joining Ibex, Daphna served as Head, Personalized Medicine and Diagnostics at Teva Pharmaceuticals, where she supported the discovery, development, differentiation, and led repurposing of Teva's pipeline drugs, in collaboration with the Israeli healthcare sector and multinational companies. Prior to that, Daphna led biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies.



► Elisabeth Kogan - CEO and Co-founder, Clexio Biosciences

Elisabeth is CEO and co-founder of Clexio Biosciences, a clinical stage Biotech focusing on developing novel therapies for patients suffering from neurological and psychiatric conditions.

Prior to Clexio, she held global leadership positions at Teva Pharmaceuticals – including Senior Vice President InnoTech, SVP Global Generic R&D, VP Global Sales & Marketing – contributing to the company's pipeline and growth.

She is passionate about bringing new solutions to patients to reduce their suffering. She is also chairwoman of Gvahim, an NGO.



► Eran Harary, MD - Senior VP, Head of Global Specialty R&D, Teva

Eran is a medical doctor and board certified in psychiatry. Eran has more than 14 years-experience in senior global managerial and leadership roles in international large pharmaceutical companies and smaller biotech companies both in Israel and in the US (including Lundbeck and Pfizer Global Headquarters in New York, USA). Experienced in world-wide Lifecycle Management of pharmaceuticals from concept through all development stages to post approval. Eran earned his MD degree from the Sackler School of Medicine in Tel Aviv, and later trained and practiced as a psychiatrist at the Chaim Sheba Medical Center, Tel- Hashomer.



► Dr. Gili Hart – CEO, SpilSense

Dr. Gili Hart is a biotech executive serving as the CEO of SpilSense (2020 to the present). Dr. Hart has broad experience in global regulatory strategic planning and interactions, partnering with large-pharma, public company roadshows and financing. In addition, she brings extensive experience in managing critical global programs ranging from discovery phase through Phase 3 clinical trials. Prior to SpilSense, Dr. Hart served as CEO of Mitoconix Bio (2017-2019). She also served as General Manager of OPKO Biologics (2014 - 2017) and as VP of Pre-clinical and Clinical Pharmacology at PROLOR Biotech during 2009 -2013, following her role as Senior Director at the company. During 2005-2007, Dr. Hart was a Research Fellow at Yale University's School of Medicine. She received cum laude Ph.D and MSc degrees from the Weizmann institute of science and graduated summa cum laude from the Technion with a Biotechnology Engineering degree. Dr. Hart published numerous papers and patents, her scientific work focused on autoimmunity diseases as well as on B and T cell maturation and migration that can directly affect inflammation and immune conditions.



► Speakers - 2022

► Hadas Banai - Head of Danel Biotech



Hadas Banai Head of Danel Biotech within Danel Group. In 2010 Hadas has founded and established Danel Biotech business unit which has evolved into Israel's leading recruitment agency in the fields of pharmaceutical, biotechnology & life sciences arenas. Hadas holds an extensive and wide range of experience within the Israeli market. Hadas holds BA in political sciences & human resources from Bar Ilan university, a reserve officer at the rank of Major in the IDF.

► Dr. Hilla Kedar - Senior Director, Head of Nonclinical Safety, Teva



Hilla holds a PhD in Zoology from Tel Aviv University, MSc in Molecular Neuroscience from the Weizmann Institute of Science and a second MSc in Applied Toxicology from Surrey University in the UK, which she completed during her years at Teva. Hilla is a certified Toxicologist, with over 13 years of experience in toxicology and drug development. Prior to working at Teva Hilla, worked in Wisebands, an Israeli start-up company developing a medical device, and in parallel was a lecturer in the Open University in Israel. Hilla is busy spreading the 'word of toxicology' and in building bridges of collaboration within Teva and with academia.

► Dr. Ianai Fishbein – Director, Head of in vitro pharmacology, Teva



Ianai has been working at Teva Abic site for the last six years. In his role as in vitro team leader at the non-clinical pharmacology department, he oversaw the establishment of a new, cell & molecular biology laboratory. Today, his team is dedicated to the pre-clinical development of new innovative drugs. Ianai received his Ph.D from the Weizmann institute's department of Neurobiology. He was recruited to Teva from his post-doctoral internship at the University of California San Francisco, where he studied the molecular mechanism underlying Parkinson's disease.

► Dr. Inbal Ben Eliezer - Associate Director, Head of in vivo pharmacology, Teva



Inbal is the head of the in vivo team at the non-clinical pharmacology Teva R&D and has 6 years experience in drug development. Before joining Teva, Inbal completed her Ph.D in the Weizmann Institute of Science in Biology, where she studied the biochemical and molecular mechanisms of women's fertility. After completing her studies, Inbal joined Teva as a Scientist in the Pharmacology department, responsible for early development of compounds. Next, she was appointed as project leader and group leader. As part of her role, Inbal is responsible for supporting compound efficacy and mode of action studies in a variety of therapeutic areas, such as neurodegeneration, autoimmune diseases, respiratory and pain.

► Speakers - 2022

► Iris Almosni - Talent Acquisition Israel Lead, Teva

Iris joined Teva in 2016, currently heading a local team and managing all Teva's Talent Acquisition and mobility activities in Israel. In addition, she is responsible for all local I&D activities, supporting a diverse and inclusive culture and workforce. Previously to her role in Teva, she was a Senior Executive Search Consultant at Gisha Shona, a leading executive search company.

Iris has over 20 years of experience in the Talent Acquisition field, specializing in senior executives and mid-level searches for global organizations.

Education: BA in Behavioral Sciences from Ben-Gurion University and MA in Labor Studies from Tel Aviv University



► Limor Lior, MSc – HR Director, Minovia Therapeutics

Limor is an experienced senior HR leader with over 18 years of experience in health-tech companies. She has deep professional knowledge of the biotech field, and personal experience as a manager. Prior to joining Minovia, Ms. Lior worked at Pluristem Therapeutics in various multi-disciplinary roles, including Manufacturing Manager and Organizational Development Senior Manager, and HRBP. She holds an MSc. in Biotechnology Engineer from the Technion. Limor is dedicated to the organization's people, culture and continuous development, and has a passion for innovative technologies that impact human life.



► Dr. Liron Rabany, Chief Scientist, Theranica

Liron is an applicative neuroscientist with nearly 15 years of experience at the intersection of academic, medical, and industry innovation. Presently, Liron is the Chief Scientist of Theranica, an Israeli-American neurotech company that develops digital health treatments for migraine and other pain disorders. Liron holds a PhD in neuroscience from Tel-Aviv University, and post-doctoral experience from the Olin Neuropsychiatry Research Center (affiliated with Yale University). Additionally, Liron has been a co-manager of the Yale chapter of ScienceAbroad, and serves as a member of the Israeli national committee for women in science and technology.



► Mati Gill - CEO, AION Labs

Mati is the CEO of d AION Labs, the Innovation Lab for AI In drug discovery and development of Pfizer, AWS, AstraZeneca, Teva, Merck and IBF. A former senior Executive at Teva Pharmaceuticals and Chief of Staff for Israel's Minister of Public Security. An IDF veteran (Maj. res.) and founder of the Sanhedrin Forum for young professionals. Mati is an attorney with an LLM and MBA in Healthcare & Innovation from Reichman University.



► Speakers - 2022

► Mia Bloch - Head of People & Operations at McKinsey Tel Aviv



Mia manages all aspects of HR at McKinsey's Tel Aviv office – recruiting, learning, HR, mobility. In particular driving McKinsey's growth journey (doubling its number of consultants in 2021, and further growing in 2022), and diversifying the talent at McKinsey Tel Aviv to ensure it is representative of Israeli society, and implementing a culture that is inclusive.

► Dr. Moshe Ben David - CTO, Ukko



Moshe Ben-David is the CTO of Ukko, a biotech startup focusing on food allergies and sensitivities. Before joining Ukko, Moshe conducted research focusing on protein engineering and structural biology in world-leading research groups. He received his MSc and PhD from the Weizmann Institute and did a postdoctoral fellowship at the University of Toronto. During his postdoctoral studies he served as the Regional Manager of ScienceAbroad in Toronto.

► Dr. Noa Molshatzki - Senior Statistician, Cytoreason



Noa Molshatzki is a statistician, researcher and R programmer that specializes with machine learning methods. Noa is a senior statistician and leads one of the computational algorithm's squads in CytoReason company. Noa holds a Ph.D in Biostatistics from the University of Southern California and a MSc in Statistics from Tel Aviv university.

► Dr. Noa Sher- Chief Scientist, Minovia Therapeutics



Noa is a highly experienced research leader in the cell therapy space and a molecular and cellular biologist by training. Noa received her Ph.D in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral studies at the Whitehead Institute, MIT, Cambridge, MA and at the Technion Institute of Technology in Israel. She joined Minovia after several years as head of a research team heading preclinical development and characterization of all clinical-stage products at Pluristem, an Israeli-based cell therapy company.

► Speakers - 2022

► Dr. Noam C. Diamant - Co-founder & CEO, NOGA Therapeutics

Noam is an experienced biopharma professional with a deep scientific background. Prior to NOGA Therapeutics, Noam co-founded Emendo Biotherapeutics, a leading genome editing company that was acquired by Angen, Japan in 2020 for \$295M. As an expert in intellectual property strategy, Noam has advised dozens of biomed companies, building their patent portfolios. Noam holds a PhD from the Weizmann Institute in the field of DNA damage repair.



► Prof. Oded Shoseyov, PhD - Plant Molecular Biology and Nano Biotechnology, The Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem

A faculty member of the Hebrew University of Jerusalem. Prof. Shoseyov's research is in plant molecular biology, protein engineering and Nanotechnology. His group focuses on Bio-Inspired Nanocomposite materials. He has authored or co-authored more than 350 scientific publications and is the inventor or co-inventor of 94 patents. Shoseyov is a TED speaker. His talk was translated to 22 languages with more than 1.8 million views. Shoseyov is also co-owner and winemaker of BRAVDO winery (<http://www.bravdo.co.il/home>) named after his mentor, and partner Prof. Ben Ami Bravdo. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002, the 1999 and 2010 Kay Award for Innovative and Applied Research, The 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation, The 2018 Presidential Award for his contribution to the Economy and Society of Israel. He is the scientific founder of 17 companies



► Dr. Omer Stern – Senior Manager, Academic Affairs and Networks, Teva

In his current role as a member of the academic affairs and networks team in Teva, Omer develops and supports research collaborations with academic partners, as well as scouting for scientific innovations. Prior to Teva, Omer was a biomarker specialist and a project leader at F-star therapeutics, Cambridge UK, developing bispecific antibodies for immunotherapy, working both at the discovery stage and on clinical and translational development. Prior to that Omer was a postdoctoral researcher in Cambridge at the MRC Laboratory of Molecular Biology (LMB), where he studied the endocytosis of antibody-drug conjugates. Omer holds a PhD in Clinical Immunology and Microbiology from Tel Aviv University.



► Dr. Oren HersHKovitz - CEO, Enlivex Therapeutics

Oren HersHKovitz is the CEO of Enlivex Therapeutics Ltd since 2019 (ENLV). Prior to that, Dr. HersHKovitz served for nearly a decade in managerial and executive roles at PROLOR Biotech, Inc. and OPKO Biologics, Ltd., acting as General Manager for the past 4.5 years. Dr. HersHKovitz successfully led the manufacturing, non-clinical and clinical development of various programs including a long acting growth hormone, which successfully completed a Phase 3 study under a licensing agreement with Pfizer, and recently approved in Canada, Australia and EMA.



► Speakers - 2022

► Dr. Pini Orbach - Head of Pharma, Arkin Holdings



Dr. Pini Orbach joined Arkin Holdings in 2010 as head of its pharma division. He sits on the board of several of Arkin's pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, with which he shares his extensive hands-on experience in drug development and business.

Dr. Orbach's gained his professional record in US-based companies such as Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ: EPIX), as well as Israel-based companies such as cCAM BioTherapeutics, a cancer immunotherapy company sold to Merck in 2015 for \$605M

He holds a Ph.D from the department of physiology and functional genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School, Massachusetts General Hospital.

► Rony Lann, CEO - L-il Executive Search



Rony combines 20 years of executive search and Human Resources management experience. Throughout the years she planned and directed a full complement of human resources programs for managers and employees located across the globe and she managed the recruitment of hundreds of positions. In 2008, Rony established L-il Executive Search Ltd., a boutique executive search group, specializing in placing top professionals in leading positions in Israel and abroad. The company rapidly became a leading executive search company in Israel.

Having lived both in Israel and the US, Rony has established a wide network which provides exceptional search services for our clients with an emphasis on executive positions.

Rony holds an M.A. in Organizational Studies.

► Prof. Shai Shen-Orr - Chief Science Officer, CytoReason



Systems biologist and data scientist Shai Shen-Orr, is a co-founder and Chief Scientist of CytoReason. He is also a Professor in the Faculty of Medicine at the Technion, directing the Systems Immunology & Precision Medicine lab. Shai is devoted to developing new analytical methodologies for grappling with the intricate complexities of the immune system, and their application in drug development. Shai holds a Ph.D. in Biochemistry from Harvard University and an M.Sc. in Bioinformatics from the Weizmann Institute of Science. He completed his postdoctoral studies at Stanford University School of Medicine.

► Dr. Sara Shnider - Associate Director, Academic Affairs and Networks, Teva



Sara has been with Teva for 5 years in the US and Israel. In her current role she is responsible for technology scouting and managing academia-industry research collaborations according to the company strategic priority areas. She also serves as project coordinator for Teva's engagement in European public-private consortia. Prior to Teva, Sara was executive director of Prize4Life, a non-profit organization focused on accelerating therapy development for neurodegenerative diseases. Previously, Sara was responsible for negotiating industry-academia research contracts and clinical trial agreements as an Industry Contract Officer in the technology transfer office of UCSF, one of the top academic medical centers in the US. She obtained her Ph.D. in Molecular and Cellular Biology from Harvard University, and her M.Sc. in Bioinformatics from the Weizmann Institute.

► Speakers - 2022

► Dr. Sharon Hausdorff - VP and Chief Patent Counsel, Teva

Sharon has been with Teva for 20 years and is responsible for a global team of about 40 people who manage all pre-litigation patent work for Teva, covering generic, branded, biologic and biosimilar products, as well as medical devices. Before joining Teva, Sharon was Manager of IP and licensing at ARIAD Pharmaceuticals. She earned her B.A. in Biochemistry from Barnard College and her Ph.D. in Biochemistry from Brandeis University, and following a postdoctoral fellowship, was appointed Instructor in Medicine at Harvard Medical School. She is a registered US patent agent and an Israeli patent attorney.



► Dr. Shmulik Hess - CEO Valin Technologies

Dr. Hess is the CEO of Valin Technologies, received his Ph.D in Pharmaceutical Science from the Hebrew University, Israel and was a research fellow at Harvard-MIT Health Sciences and Technology. Dr. Hess was CEO of Enlivex (\$ENLV) a cell therapy company. Dr. Hess was founder and CEO of ActivePx, engaged in the development of peptides for the treatment of pain. Following which he served as associate global operations at Scigen. Dr. Hess is co-founder and chairman of ScienceAbroad an NGO dedicated to encouraging and supporting the return Israeli scientists from abroad.



► Tali Bonjack - HR Director, Cytoreason

Tali is CytoReason's Director of HR. She started her career at Intel, and has over 15 years of experience in varied human resource disciplines, specializing in HR management, management consulting, career development, and organizational development. She is an MBA graduate from Tel Aviv University.



► Dr. Tami Dvash - VP R&D for Meat Products, Aleph Farms

Dr. Dvash is an expert with over 10 years of experience in stem cell biology and product development in the biotechnology industry. Before joining Aleph Farms, she was the VP of R&D at the biotech company SYNERGIO, where she led the development of natural antimicrobial solutions for the personal care industry. Prior to this role, Dr. Dvash served in various positions at Merck KGaA (formerly Sigma Aldrich), notably as the Head of R&D department which focused on developing multiple off-the-shelf products in the microbiome and natural bioactives field. Prior to her industrial experience, she performed her postdoctoral research at UCLA where she researched epigenetics in pluripotent stem cells. Dr. Dvash holds a PhD in Human Genetics and stem cell biology, M.Sc. in Human genetics and a B.Sc. in Medical sciences from the Hebrew University in Israel. In 2022 Dr. Dvash joined Aleph Farms as the VP of R&D for meat products.



Dr. Uri Weinberg - Chief Science Officer, Novocure



Dr. Uri Weinberg currently serves as Novocure's Chief Science Officer overseeing early-stage research and development as well as the design, development and implementation stages of all clinical trials. Since joining Novocure in 2008, he has held several positions throughout his tenure with the company. Dr. Weinberg managed Novocure's first clinical trial in lung cancer as well as the EF-14 clinical trial in newly diagnosed glioblastoma and built the company's global Clinical Operations team in Switzerland. Dr. Weinberg most recently held the position of Vice President of Clinical Development where he was responsible for expanding research activities, strengthening global clinical collaboration and initiating new discovery programs. Dr. Weinberg holds an MD/PhD from the Technion - Israel Institute of Technology

Dr. Yael Marantz – VP and Head of Nonclinical Development, Head of ABIC Teva's Innovative R&D site in IL, Teva



Yael received her bachelor's degree in chemistry, her Master's degree in biochemistry, focusing on signal transduction of the GnRH receptor, and a PhD in biophysics, on proton transfer mechanism in Cytochromes, all from Tel Aviv university.

Yael was a founding scientist in a biotech company called EPIX pharmaceutical - a pharmaceutical company based in Lexington MA and Ramat-Gan IL, developing drugs for CNS and inflammation (GPCR's). Yael was involved in the discovery of all the company pipeline (four of them reached clinical trials) and served as a VP computational drug development, head of the IL site (30 employees) a member in the executive team, as well as a member of joint research committees with GSK, Amgen and the CFTR foundation. Yael joined Teva 10

years ago as a project champion for four biosimilars. As part of her role, she developed early clinical plans, set the overall work plan and interacted with many functions in the company including commercial, IP, nonclinical, clinical etc. Later on Yael assumed for a short period the role of a project champion for both Azilect and Copaxone focusing on LCM activities, new clinical trials, NDA preparation for new Azilect formulation (not submitted) and preparation for the approval of the 40mg Copaxone. Soon after the Cephalon integration, Yael assumed the role of head of nonclinical. Through these years this role has evolved and she is now responsible for a global group of 130 people in the fields of Tox, DMPK, pharmacology as well as bioanalytical/immunogenicity and biomarkers assays group, the academic affairs and networks group and supports the specialty, generic and TGO organization in various aspects. Through her years in Teva, Yael participated in many company initiatives such as Spring, STEP and was part of the team working on our company leadership framework. In the later years she was also the head of the Teva ABIC site in Netanya (the specialty R&D site of Teva in IL).

Prof. Yanay Ofra - CEO, Biologic Design



Prof. Ofra, a biophysicist, heads the Lab of Systems Biology and Functional Genomics at Bar Ilan University in Israel.

Prof. Ofra is also the founder and CEO of Biologic Design, a biopharmaceutical company using AI to design new biological drugs. He is the co-founder and Chairman of Ukko, a startup combining AI with advanced genome technologies to solve food allergies and sensitivities. Prof. Ofra is also the Co-founder of Aulos Bioscience, a clinical stage company that uses computationally designed antibodies to treat cancer. Prof. Ofra received his PhD in molecular biophysics and biomedical informatics from Columbia University, and is the author of over 100 papers and patents.

Dr. Yaron Daniely - Partner & Head of aMoon Alpha



Yaron Daniely is a Partner & Head of aMoon Alpha, an internal value creation unit charged with translating aMoon's unique scale, talent and global network into concrete competitive advantages and growth opportunities for our portfolio companies. He is also an investment leader at aMoon Velocity, our early stage investment fund that pursues disruptive, cutting-edge technologies with the potential to accelerate cure.

Born in Israel and raised in Florida, Yaron was fascinated by science, medicine and technology from a young age. Driven by a passion for discovering and creating novel solutions, and a persistent quest for challenging the status quo wherever he went,

Yaron spent much of his career leading innovative health tech companies. He brings to aMoon a wealth of hands-on experience as a business leader in both the private and public sectors.

In return, aMoon fulfills his craving for cutting-edge science and strategic thinking, applied to the creation and mentorship of young companies focused on impacting people's health.

Prior to aMoon, Yaron was the President and CEO of Yisum, Hebrew University's acclaimed Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network (ITTN), where he converted academic research into practical products and technologies. Before leading Yisum, he spent 14 years as a senior executive - and 10 years as CEO - of private and NASDAQ-traded Biopharma and Biotech companies. He also co-founded and served for ten years as the director of Israel's first and leading MBA program for professionals of the local Biomedical industry at the College of Management Academic Studies.

Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine.

Following his doctoral program, he served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion - Israel Institute of Technology.

Prof. Yesha Sivan - CEO & founder, DigitalRosh

Prof. Yesha Sivan the founder and CEO of i8 ventures (<http://i8.ventures>) – a business platform focusing on “Innovating innovating.” He is also an MBA visiting professor focusing on digital, innovation, and venture at the Technion – Israel Institute of Technology. Sivan's professional experience includes developing and deploying innovative solutions for corporate, hi-tech, government, and defense environments. He focuses on digital strategy (SVIT – Strategic Value of Innovation Technology), innovation and venture (employment black holes), mindful leadership (orange bike workshop), virtual worlds (3D3C platforms), and knowledge age standards (nine keys). After receiving his doctorate from Harvard University, he has taught executives, EMBA, MBA, engineering and design courses in his areas of expertise



Dr. Yuval Cabilly - Co-Founder and Managing Partner, IBF – Israel Biotech Fund

Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Cabilly has vast experience in identifying, funding and engaging in business development activities of Israeli biotech companies. Dr. Cabilly received his PhD in molecular cell biology from Tel Aviv University, where he focused his research on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals.



Mr. Zohar Gendler - Managing Partner and CEO, NGT3

Managing Partner & CEO of NGT3 which is an early-stage investor structured as a venture capital fund and a holder the Israeli government franchise to operate technological incubator and invest in life-science technologies. NGT3 portfolio currently includes a diverse portfolio of 20 companies in the fields of medical devices, biotech and pharma. Former CEO and director of Beta-O2 Technologies for a period of 8 years (a biomedical company which developed proprietary implantable bio-artificial pancreas), brought the company to one of the world leaders positioning in the area. Served as CEO of the Technion Entrepreneurial Incubator for a period of 11 years. Led the establishment and investment in more than 50 companies, such as Prolor Biotech (sold to Opko, for \$480M), Mazor Robotics (sold to Medtronic, for \$1.6B), ReWalk (NASDAQ: RWLK, www.rewalk.com), Corindus (sold to Siemens Healthcare, for \$1.1B), Regentis (www.regentis.co.il), Medic Vision (<http://www.medicvision.com/usa/home>), and many others. Gained a wide range of experience in identifying new technologies and in establishing, directing, and creating value for technology-based start-up companies. Served as a member of the Technion's Patent Committee. (1998 – 2006). Earned his M.Sc. in material engineering, a B.Sc. in physics, and a certificate in business management, all from the Technion, Israel Institute of Technology.



► Participants – 2022

► Dr. Amitai Zuckerman



Amitai completed his Ph.D. studies at Ben Gurion University in the lab of Prof. Hagit Cohen. In his Ph.D., he developed an animal model to study blast wave-induced mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). Following his Ph.D., he joined Dr. Victoria Johnson's lab at the University of Pennsylvania, as a postdoctoral fellow, where he studied the changes in the distribution of axonal pathology in the brain, following TBI. In 2021, he joined the lab of Prof. Zezong Gu at the University of Missouri's School of Medicine, where his postdoctoral research seeks to identify potential biomarkers and therapeutic targets for Chronic Traumatic Brain Injury. In his studies, he combines behavioral, histological, and molecular methods. In addition to academic research, he worked for more than ten years at two contract research organizations (CRO's) - Envigo CRS (Israel) and Pharmaseed, specializing in pre-clinical models for the biomedical and pharmaceutical industry. His extensive experience in both academic and industrial studies, gives him a thorough understanding of the field of animal-based modeling. In addition to his studies on brain pathologies, he is also interested in improving the quality and promoting the use of translational animal models.

► Dr. Anna Vitlin Gruber



Dr. Anna Vitlin Gruber is a Biochemist who is fascinated by plant development. She earned her B.Sc. (magna cum laude) in Biotechnology from Tel Aviv University (TAU), where she worked in the laboratory of Prof. Adina Breiman, studying plant adaptation to heat stress. After graduation, Anna joined the MSc Biochemistry program at TAU (magna cum laude), where she also earned her Ph.D. During her MSc and Ph.D, Anna worked with Prof. Abdussalam Azem analyzed the structure-function relationship of chloroplast chaperonins with the ambitious goal of assembling Rubisco in vitro. For her postdoctoral training, Anna joined the laboratory of Prof. Jeff Long at UCLA, where she used the model plant Arabidopsis to understand how plants maintain their stem cell niche while developing different organs. She employed genetics, imaging, biochemistry, and genomics to unravel protein interaction mechanisms of transcription factors and their effect on gene expression. Anna serves as the Regional Manager of ScienceAbroad in Los Angeles and is part of the WISER leadership team – a mentorship initiative for Israeli women postdocs.

► Dr. Avital Licht Murava



Avital completed her Ph.D. studies at Tel Aviv University under the supervision of Prof. Hagit Eldar-Finkelman. She continued her postdoctoral training with Dr. Haroutunian Vahram at the Mount Sinai School of Medicine and Dr. Anna G. Orr. at the Weill Cornell Medicine. Her current research projects focus on the effect of astrocytic TAR DNA-binding protein 43 (TDP-43) in neuropathology and cognition. TDP-43 is implicated in dementia and expressed throughout the brain, but its exact roles and pathogenic effects are unknown, especially in specific cell types. She reports that TDP-43 dysfunction in astrocytes was sufficient to cause progressive memory loss and altered neuroimmune deficits signaling involving aberrant antiviral cascades. Antiviral changes in astrocytes were associated with CXCR3-mediated presynaptic impairments and neuronal hyperexcitability. Together, these results implicate astrocytic TDP-43 dysregulation in the pathogenesis of dementia and point to antiviral pathways and chemokine signaling as potential therapeutic targets for alleviating cognitive decline.

► Participants – 2022

► Gabriel Javitt, PhD candidate

Gabe received his B.Sc. degree (magna cum laude) in Biotechnology and Food Engineering from the Technion. He conducted research in the lab of Prof. Ayelet Fishman on mutating enzymes for industrial applications. He will be completing his Ph.D. studies (direct track) in Biochemistry and Structural Biology from the Weizmann Institute in the lab of Prof. Deborah Fass. His primary research focuses on understanding the shared molecular assembly mechanism of the mucin family of proteins that form the mucosal barrier in the lungs and intestines and of the von Willebrand Factor, which initiates blood clotting. Using structure-based techniques (crystallography, cryo-EM, and cryo-ET), biochemistry, and molecular modeling, he produced the first high-resolution structures of these proteins and understood how they form into biopolymers. Gabe's research interests include molecular biology, biotechnology, and advanced microscopy.



► Dr. Galit (Gali) Fichman

0502727414

Gali recently completed her postdoctoral training at the National Cancer Institute, NIH, in the Chemical Biology Laboratory (Joel Schneider group). She received a Ph.D. and M.Sc. in Biotechnology from Tel Aviv University, under the supervision of Prof. Ehud Gazit, and holds a B.Sc. in Biotechnology Engineering from Ben-Gurion University. Her postdoctoral work centered on peptide-based materials, focusing on applied and basic research using self-assembling systems. In her main project, Gali focused on clinical-oriented material development, where she developed a new class of peptide-based antibacterial gel coatings to prevent implant-related infections. In her other projects, Gali developed different strategies to modulate and fine-tune the mechanical properties of peptide-based gels, a highly desirable feature for specific biomedical applications such as drug delivery and tissue engineering. In addition, in her graduate studies, Gali designed and characterized peptide motifs that self-assemble into functional nanostructures; this work resulted in two patent applications. In her M.Sc. studies, Gali focused on synthetic biology. Using molecular biology tools, she developed a selection system to allow in vivo site-specific incorporation of non-natural amino acids into proteins. Gali has a unique interdisciplinary background in engineering, biology, chemistry, and materials science. She is an expert in self-assembling systems and material characterization at the nano, micro, and macro-scale. As of July 2022, Gali will be joining the Institute of Biochemistry, Food Science, and Nutrition, the Faculty of Agriculture, Food and Environment, the Hebrew University of Jerusalem as an assistant professor. Her lab will focus on soft-matter and functional biomaterials for the food industry and biomedical applications.



► Dr. Idan Frumin

Dr. Idan Frumin is a neuroscientist with a flair for chemistry, technology, and education. He graduated his B.Sc at the Technion studying Molecular Biochemistry and assisting in ubiquitin pathways research and clinical electron microscopy, after which he continued to do his masters with Prof. Oren Froy at the Hebrew University. He studied biological clocks from the molecular, cellular and up to systems and behavior in mice brains and groups, and tried to make them live longer through the entrainment of their circadian rhythms, using light and feeding regimens. He then joined Prof. Noam Sobel's lab at the Weizmann Institute of Science Brain Sciences department, where he concluded a delightful Ph.D that focused on the human sense of smell. In particular, he researched Chemical Communication from molecules, analytical chemistry, computational modeling of perception and chemical spaces, through psychophysiology and up to brain scans, cognitive functions, and behavior - publishing exotic findings regarding human emotional tears and their magic powers, the weird science behind Handshakes amongst others...

He now resides in Seattle, Washington, where he did his postdoctoral studies at the lab of Nobel laureate Prof. Linda B. Buck - where he mapped the neural circuits and correlates of stress and feeding, using fluorescent imaging, viral tracing, and single-cell neuronal RNAseq. After Moving briefly before COVID-19 to Berlin, where a startup he co-founded regretfully had to shut down, He is currently involved in two startups as the head of research; one in Israel, a provisionally patented medical device which he'll discuss during the workshop, and the other in Brazil, a biotechnology farm operation.



► Participants – 2022

► Dr. Irit Miller Zmora



Dr. Irit Miller Zmora is a postdoctoral fellow at the School of Dentistry, University of California San Francisco, in Ophir Klein lab. In her research, she seeks to understand how pathophysiological conditions affect oral epithelium regeneration. She focuses on the effects of tobacco-related products and whether impairing the integrity of the oral barrier promotes the onset of oral diseases. Additionally, she is interested in how electric-cigarette compounds disrupt taste bud regeneration. Dr. Miller Zmora received her Ph.D. from Tel-Aviv University in Medical Science. Her research focused on pigment epithelium-derived factor (PEDF) as an ovarian regulator of angiogenic and inflammatory pathways in fertility-related syndromes.

► Lavi Bigman, Ph.D candidate



Lavi is a soon-to-graduate computational biophysicist in the lab Koby Levy at the Weizmann Institute of Science. In his Ph.D work, he used a combination of molecular dynamics simulations, bioinformatics, and physical modeling the study molecular mechanisms of protein trafficking on microtubules and DNA. Lavi also worked on biophysical quantification of disordered protein regions and entropic contribution to protein stability. Lavi got his MSc in the lab of Amnon Horovitz at the Weizmann Institute, and received a BSc in Physics and Chemistry from the Hebrew University.

In addition to his scientific work, Lavi writes popular science content for the website of the Davidson Institute for Science Education on various scientific topics. From time to time he enjoys discussing science on national radio and TV shows. Lavi was a fellow of the National Forum for BioInnovators (class of 2021) and now serves as a mentor in the forum.

► Dr. Lior Almagor



Dr. Lior Almagor is a research scientist in the Departments of Structural Biology and Molecular & Cellular Physiology at the Stanford University School of Medicine. He started his role at Stanford as a postdoctoral fellow in 2014 after a short postdoctoral fellowship at Tel Aviv University, where he also received his Ph.D. in Biochemistry. His current research aims to understand the molecular mechanisms by which epithelial cells develop and maintain their apical-basal polarity. He studies the relationship between a group of specialized proteins that control this polarity by segregating each other to separate parts of the cell's membrane. Throughout his academic career, Dr. Almagor has been interested in understanding the mechanistic basis of protein function and the transaction of signals by molecular interactions. He is an experienced structural biologist using cryo-electron microscopy and X-ray crystallography to determine high-resolution structural data and a wide variety of other techniques to pursue his scientific interests. In his earlier postdoctoral fellowship at Tel Aviv University School of Medicine, his structure-based study on an archaebacterial sodium/calcium transporter led to significant mechanistic insight into the mechanisms of ion transport of this family of ion transporters. His doctoral work at Tel Aviv University analyzed the interaction between subunits of voltage-dependent calcium channels and its effect on the channel's electrophysiological properties of inactivation.

► Participants – 2022

► Dr. Nir Ben-Chetrit

Nir Ben-Chetrit, Ph.D is a Postdoctoral Associate in Medicine at Weill Cornell Medical Center. His research in cancer immunology seeks to uncover immune evasion mechanisms promoted by tumor-associated macrophages during tumor growth and metastasis. He earned his Ph.D. in cancer biology at the Weizmann Institute of Science, under the supervision of Prof. Yosef Yarden. He continued his postdoctoral training with Prof Johanna Joyce at the Memorial Sloan Kettering Cancer Center and Dr. Dan Landau at Weill Cornell Medicine/New-York Genome Center NY.

His previous work focused on ECM remodeling and cell-intrinsic growth mechanisms that propelled triple-negative breast cancers invasion and metastasis and yielded novel translational agents for therapeutic interventions.

To identify new potential therapeutic targets, he currently focuses on identifying immunosuppressive mechanisms of the innate immune system. He recognized the unmet need to model the complexity of the tumor microenvironment and target education signals of macrophages in a system that allows high throughput interrogation of cell-cell interactions, which are limited in animals.

He developed a novel and scalable organotypic TME model that captures the cardinal interactions between mammary tumor cells, fibroblasts, T cells, and macrophages while providing read-outs suitable for drug-based and genomic screenings. He was able to enhance the translational potential of human disease and apply a phenotypic “M2-education” CRISPR screen in primary macrophages to uncover druggable gene targets essential for maintaining immunosuppressive traits.



► Dr. Noga Gal

Dr. Noga Gal has obtained her Ph.D from the University of Natural Resources and Life Science, in Vienna, focuses on the study of the cellular interaction of superparamagnetic iron oxide nanoparticles, in the bio-inspired materials group, led by Prof Erik Reimhult.

She continued to do a post-doc at Aarhus University, Denmark in the cell mimicry group led by Assoc. prof. Brigitte Stadler. The group focuses on creating artificial organelles for therapeutic. Noga's main project focused on sensor development for rapid testing of solvents, e.g., beverage safety and quality, virus and pathogen detection, composition analysis etc. The project led to a spin-out company, BettaSensing, in which Noga is the CTO and co-founder. Combining scientific research with the world of entrepreneurship, Noga does not shy away from a challenge and is keen to tackle new tasks and broaden her expertise and experience.



► Dr. Reut Shainer

Dr. Reut Shainer is a postdoctoral research fellow in the Molecular Biology of Bones & Teeth Section at the National Institutes of Health (NIH), seeking to understand the role of the small matrix proteoglycan, Biglycan, in bone formation and regeneration. Reut started her academic journey at Tel Aviv University where she completed her B.Sc. She later received her M.Sc. (cum laude) from the Faculty of Medicine at the Hebrew University, where she examined the efficacy of new 3D scaffolds for cartilage tissue engineering. Reut continued her Ph.D study in the Department of Bone Marrow Transplantation at Hadassah Hebrew-University Medical Center, where she studied the effect of the small embryonic peptide on the immune response in several overactive immune diseases for preclinical research. Before heading to her fellowship at the NIH, Reut did a short postdoctoral fellowship at the Hebrew University, where she produced and purified proteins for vaccine development.



► Participants – 2022

► Dr. Rinat Meir



Rinat is a multidisciplinary scientist dedicated to leveraging materials design, bioengineering, and computations, to improve human health. As a postdoctoral research scientist at the Department of Chemistry at Columbia University in the city of New York, she has been developing innovative light-responsive polymeric hydrogels, for next-generation tissue engineering and 3D bioprinting. Rinat began her academic studies with a B.Sc. in Chemistry and M.Sc. in Computational Chemistry at the Hebrew University of Jerusalem, under the supervision of Prof. Sason Shaik. She then conducted her Ph.D. research in the lab of Prof. Rachela Popovtzer at Bar-Ilan University's Nanotechnology Center, where she focused on the design of a novel nanoparticle-based drug delivery platform for advanced imaging and targeted cancer immunotherapy. Rinat is a recipient of several prestigious prizes and awards including the Wolf Foundation Scholarship, the Dan David Prize, and the Fulbright Postdoctoral Award.

► Dr. Smadar Bustan



Smadar Bustan, Ph.D (FRANCE) is a clinical researcher, experimental scientist, and ethicist. During her work in Luxembourg, Germany, and France, she used a multidisciplinary approach to medical research and patient care, inventing a healthcare assessment tool of suffering associated with chronic illnesses related to pain and cancer. She co-founded at Harvard and heads the International Program on Suffering and Pain (www.suffering-pain.com). She recently initiated work on Ethical Dilemmas in Healthcare during the COVID-19 pandemic.

► Dr. Tal Pecht



A postdoctoral researcher in the group of Prof. Joachim L Schultze at LIMES (Life and Medical Sciences) in Bonn, Germany. Tal investigates the variation of the human immune system, with a focus on the female immune system, using multi-omics techniques, including RNAseq and scRNAseq. Her current work includes the "Femmunity study" in Bonn, which aims to leverage the power of functional genomics and scRNA-seq in order to study the oscillation of the peripheral female immune system during the menstrual cycle. Her skills include both wet-lab immunological assays and bioinformatics. Tal is an active and contributing member of the academic community, including managing the ScienceAbroad branch in the Rhineland region in Germany and serving as vice-spokesperson of the Young Immunologists of the German Society of Immunology (DGfi).

► Participants – 2022

► Dr. Tal Raveh

At Stanford Tal was involved in the initial development of CD47 blockade as new cancer immunotherapy and gained experience in translational research. As a research associate, she directed the brain cancer research team, conducted pre-clinical studies, studied a xenograft model with brain tumor samples from patients, and showed the efficacy of anti-CD47 antibodies in treating both adult and pediatric brain tumors. She then founded a consulting company, "Science Works", and provided scientific consulting for research program development, grant applications, and publications in the fields of stem cell biology, cancer biology, and Immunotherapy. She was then recruited back to Stanford to work with Prof Weissman's team at the Stanford Institute for Stem Cell Biology and Regenerative Medicine, focusing on the further development of macrophage checkpoint immunotherapy for cancer and infectious diseases.

Since the beginning of the pandemic, Tal conducted a community outreach giving lectures and articles to educate the general public about the science of COVID19.

Tal holds a B.Sc. in Life Science from Tel Aviv University with a focus on microbiology, and Ph.D in cancer biology from the department of molecular genetics at the Weizmann Institute.



► Dr. Yelena Lalazar

Yelena Lalazar is a Clinical Development and Operations professional with over 10 years of experience in global phase I-III pharmaceutical trials in various therapeutic areas. Her expertise encompasses clinical trial planning, start-up activities, CRO and vendor selection, set up and oversight, global study team management, study closeout, and CSR. During her career at Novartis, she managed the Phase II registration trial of the first approved cell therapy "Kymriah" for Pediatric and young adults r/r ALL. In addition, she led the first combination trial for DLBCL with Kymriah and Pembrolizumab. In her current position as Associate Director of Clinical Operations at Zentalis Pharmaceuticals, Yelena is leading 2 phase II studies for ZN-c3 (WEE1 inhibitor) for oncology indications.

She received her bachelor's in nursing and master's in Public Health from the Hebrew University. Previously, Yelena worked for over 12 years as a clinical nurse at Hadassah Medical Center Emergency Department and 4 years as Clinical Manager for the Pituitary Center at Mount Sinai Hospital New York, NY.



► Dr. Yogev Sela

Yogev earned his Ph.D as a joint student of Prof. Yoav Soen from the Weizmann Institute and Prof. Joseph Itskovitz-Eldor from the Technion where he studied embryonic stem cell differentiation. As a postdoctoral fellow in the lab of Prof. Ben Stanger at the University of Pennsylvania, he specialized in tumor heterogeneity, metastasis and drug resistance. In his work, Yogev strived to understand the functional building blocks of cancer and define not only how to target tumor cells but also what are the cells to be targeted. In two recent studies, he developed new tools to model understudied tumor cell populations including occult metastatic cells, and nutrient-deprived quiescent tumor cells and demonstrated the importance of a phenotype-centric approach to drug design. Yogev was also a part of team effort in the Stanger lab to improve immunotherapy in pancreatic cancer by turning cold tumors into hot tumors.



► Participants – 2022

► Dr. Ziv Azoulay



Ziv Azoulay is a postdoc fellow at the Ben-Gurion University Department of Biotechnology Engineering. Originally a chemical engineer with 5 years experience in process engineering, Ziv has completed his postgraduate studies in researching peptide self-assembly for biomedical applications. In the recent year, he's been developing nanobodies targeting cell membrane receptors to mitigate breast cancer in Niv Papo's lab which specializes in protein engineering. He is interested in producing recombinant proteins-based drugs.

// Great minds think ISRAEL //

מלגות הטיסה במימון



תודתנו לנותנת החסות



תודה למארחי הסדנה



תודה לכל שותפינו



Contact Information:

Gali Timor
gali@scienceabroad.org.il
Cell: 052-4496418

Nadav Douani
nadav@scienceabroad.org.il
Cell: 054-7573121

Dana Bar-On
Dana.Bar-On@teva.co.il
Cell: 052-3495359

www.scienceabroad.org.il